ARTICLE | Clinical News
KTE-C19 regulatory update
November 11, 2016 8:55 PM UTC
Kite said it plans to begin by year end the submission of a rolling BLA to FDA for KTE-C19 to treat non-Hodgkin's lymphoma (NHL). The company plans to complete the submission by the end of next quarte...
BCIQ Company Profiles
BCIQ Target Profiles